Pathstone Holdings
VTVT icon

Pathstone Holdings’s vTv Therapeutics VTVT Stock Holding History

Pathstone Holdings’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$241K Hold
6,073
– – ﹤0.01% 2043
2025
Q4 		$243K Buy
+6,073
New +$169K ﹤0.01% 2042

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Pathstone Holdings's VTVT Position: Q1 2026 in Review

Pathstone Holdings held its vTv Therapeutics (VTVT) position steady in Q1 2026 at 6,073 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Pathstone Holdings first reported a position in VTVT in Q4 2025 and has held it in 2 quarters since. The position peaked at $243K in Q4 2025. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

  • Pathstone Holdings held 6,073 shares of vTv Therapeutics worth $241K as of Q1 2026.
  • Pathstone Holdings left its vTv Therapeutics share count unchanged in Q1 2026.
  • vTv Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q1 2026, its #2043 holding.
  • Pathstone Holdings first reported a position in vTv Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pathstone Holdings's vTv Therapeutics position peaked at $243K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.